Jennifer Choe
Medical Oncology · Nashville, TNNPI 1912290719
Payments from drug & device makers
Across 324 payments — averaging $12,603 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.2M
- Astrazeneca UK Limited$1.2M
- AstraZeneca$452K
- Amgen$344K
- Coherus Oncology, Inc.$186K
- Regeneron$180K
- plus $472K from 16 others
Across 15 payments — averaging $215.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 149 | $1,241,633 |
| Astrazeneca UK Limited | 9 | $1,207,424 |
| AstraZeneca | 21 | $452,193 |
| Amgen | 4 | $343,621 |
| Coherus Oncology, Inc. | 21 | $185,890 |
| Regeneron | 50 | $180,095 |
| Genentech, Inc. | 12 | $131,213 |
| Genmab U.S., Inc. | 1 | $123,326 |
| Exelixis Inc. | 33 | $104,965 |
| GSK | 1 | $93,906 |
| E.r. Squibb & Sons, L.L.C. | 5 | $5,333 |
| Eisai Inc. | 4 | $4,185 |
| Dr.reddy's Laboratories,inc. | 1 | $3,500 |
| Bayer | 5 | $2,520 |
| Regeneron Healthcare Solutions, Inc. | 1 | $2,100 |
| Blueprint Medicines Corporation | 1 | $1,069 |
| Janssen Scientific Affairs, LLC | 1 | $146 |
| Genentech USA, Inc. | 1 | $68 |
| Pfizer | 1 | $56 |
| Sanofi | 1 | $50 |
| Foundation Medicine, Inc. | 1 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $27 |
How this compares
$4,083,347 in reported general payments places this provider in the 90th percentile of 101 medical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Nashville
- Melissa JohnsonNashville$46M
- David SpigelNashville$29.7M
- Howard BurrisNashville$12.2M
- Ingrid MayerNashville$6.3M
- Cathy EngNashville$3.8M
- Jordan BerlinNashville$3.7M
- Kristen CiomborNashville$3.2M
- Vandana AbramsonNashville$3M
- Leora HornNashville$2.6M
- Robert RamirezNashville$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.